The upcoming session will be hosted via a live webcast and teleconference, allowing direct engagement with the company’s leadership. CEO Peter Forsell and CFO Andreas Öhrnberg will lead the discussion alongside Chief Corporate Affairs Officer Nicole Pehrsson. Investors intending to join the teleconference must register in advance to receive access credentials and dial-in details, while the webcast will be available through a dedicated portal on the company's investor relations site.
Implantica Sets Q2 2026 Financial Results Briefing
Implantica AG has scheduled an investor presentation for August 21, 2026, at 15:00 CEST to detail the company's financial performance during the second quarter. The interim report, covering the three-month period, will be released publicly earlier that morning at 8:00 a.m. CEST to provide stakeholders with advance data.
Based in Vaduz, Liechtenstein, Implantica specializes in implantable medical technologies, most notably the RefluxStop system for gastroesophageal reflux disease. The company, which is listed on the Nasdaq First North Premier Growth Market in Stockholm, continues to develop its patent-protected pipeline, including remote monitoring and wireless powering platforms for medical devices.
Comments (0)
No comments yet. Be the first!